1SAMSON A L, MEDCALF R L. Tissue -type plasminogen activator: a muhifaceted modulator of neurotransmission and synaptic plasticity[J]. Neuron, 2006, 50(5): 673-678.
2MOON L D, MADAN! R, VASSALLI J D, et al. Neuronal overexpression of tissue - type plasminogen activator does not enhance sensory axon regeneration or locomotor recovery following dorsal he- misection of aduh mouse thoracic spinal cord[J]. J Neurosci Res, 2006, 84(6) : 1 245- 1 254.
3HENNEBERT O, LAUDENBACH V, LAQUERRIERE A, et al. Ontogenic study of the influence of tissue plasminogen activator( t -PA) in neonatal excitotoxic brain insult and the subsequent microglia/macrophage activation[ J]. Neuroscience, 2005, 130(3) : 697 -712.
4GRAVANIS I, TSIRKA S E. Tissue plasminogen activator and glial function[J]. Glia, 2005, 49(2): 177 -183.
5POLAVARAPU R, GONGORA M C. Tissue- type plasminogen activator - mediated shedding of astrocytic low - density lipoprotein receptor - related protein increases the permeability of the neurovascular unit[J]. Blood, 2007, 109(8) : 3 270 -3 278.
6MELCHOR J P, STRICKLAND S. Tissue plasminogen activator in central nervous system physiology and pathology[ J]. Thromb Haemost, 2005, 93(4): 655-660.
7HU K, YANG J, TANAKA S, et al. Tissue - type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase- 9 gene expression[ J]. J Biol Chem, 2006, 281(4): 2 120-2 127.
8KUMADA M, NIWA M, HARA A, et al. Tissue type plasminogen activator facilitates NMDA - receptor - mediated retinal apoptosis through an independent fibrinolytic cascade[ J]. Invest Ophthalmol Vis Sci, 2005, 46(4) : 1 504 -1 507.
9BENNUR S, SHANKARANARAYANA RAO B S, PAWLAK R, et al, Stress - induced spine loss in the medial amygdala is mediated by tissue - plasminogen activator [ J ]. Neuroscience, 2007, 144(1): 8-16.
10ROELOFS J J, ROUSCHOP K M, LEEMANS J C, et al. Tissue -type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury [J]. J Am Soc Nephrol, 2006, 17(1): 131-140.
4Hack W,Kaste M,Fieschi C. The ECASS s(udy group intravenous thrombolysis with recombinant tissue plasminnogen activator for acute hemispheric stroke: The European cooperative acute stroke study(ECASS) [J]. JAMA, 1995,274 : 1017 - 1025.
5The national institude of neurological discorder and stroke rt - PA stroke study group. Tissue plasminogen agents activator for acute ischemic stroke[J]. N Eng J Med, 1995,333 : 1581 - 1587.
6Rao MA,James FH. Tissue plasminogen activator (tPA) and ma- trix metalloproteinases in the pathogenesis of stroke : Therapeutic strategies[J]. CNS Neurol Disord Drug Targes, 2008,7 (3) : 243 - 253.
7Jose P, Lopez - Atalaya, Benoit D, et al. Recombinant desmodus ro tundus salivary plasminogen activator crosses the blood brain barrier through a low - density lipoprotein receptor - related pro- tein- dependent mechanism without exerting neurotoxic effects [J]. Stroke, 2007,38:1036-1043.
8Nicole O,Doeaqne F. The proteolytic activity of tissue- plasmino- gen activator enhances NMDA receptor - mediated sighaling[J]. Nature Medicine,2001,7(1) :59 - 64.
9Xiaoying Wang,Kiyoshi Tsuji. Mechanisms of hemorrhagic trans- formation after plasminogen activator reperfusion therapy for is chemic stroke[J]. Stroke, 2004,35:2726 - 2730.
10Francoise Maupas - Schwalm, Nathalie Aug,. The sphingomyelin/ ceramide pathway is involved in ERK1/2 phosphorylation,cell pro- liferation,and uPAR overexpression induced by tissue- type plas minogen activator[J]. FASEB J, 2004,18(12): 1390 - 1400.
